Merck Gets EU Approval for Keytruda in Classical Hodgkin Lymphoma
March 17 2021 - 7:47AM
Dow Jones News
By Colin Kellaher
Merck & Co. on Wednesday said the European Commission
approved the expanded use of its cancer drug Keytruda in adults and
children with relapsed or refractory classical Hodgkin
lymphoma.
The Kenilworth, N.J., drugmaker said the approval covers
Keytruda as a monotherapy for patients ages 3 and older who have
failed autologous stem cell transplant or following at least two
prior therapies when transplant isn't a treatment option.
Merck said the approval marks the first pediatric indication in
the European Union for Keytruda, which harnesses a patient's immune
system to fight tumors.
Classical Hodgkin lymphoma accounts for more than 90% of cases
of Hodgkin lymphoma, a cancer of the lymphatic system, which is
part of the immune system.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 17, 2021 07:32 ET (11:32 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024